Diabetes is a worldwide pandemic calling for innovation in therapeutic prevention and cure. Mounting evidence attribute the involvement of multiple immune dysfunctions in both type 1 diabetes (T1D, caused by autoimmunity) and type 2 diabetes (T2D, caused by insulin resistance).

"Stem Cell Educator therapy" is the innovative technology developed by Dr. Yong Zhao that uses stem cells drawn from human cord blood to targets autoimmune diseases. Currently, Tianhe is focusing on the application of Stem Cell Educator therapy in diabetes. Our clinical data provide powerful evidence that Stem Cell Educator therapy can balance the immune system and lead to the regeneration of islet beta cells and improve metabolic control in long-standing diabetic subjects. This groundbreaking technology is taking steps towards the ultimate cure of diabetes and revolutionizing the treatment of other autoimmune-related diseases.

Tianhe Stem Cell Biotechnologies Inc. has licensed a series of patented technologies from the isolation of human cord blood-derived multipotent stem cells (CB-SCs) to clinical applications. It has a major division in China, Jinan Tianhe Stem Cell Biotechnology Co., Ltd., located in Jinan High-tech Bioindustry Park District.

22, 2015,
A new Phase I/II clinical trial in autoimmune disease Alopecia Areata has been published in BMC Medicine, titled” Hair Regrowth in Alopecia Areata Patients Following Stem Cell Educator Therapy”. Findings from this trial provide visible evidence that Stem Cell Educator therapy can control the autoimmunity and lead to hair regrowth.   

April 14, 2015, Dr.Yong Zhao presented the clinical data from Spanish clinical trial at Immunology of Diabetes Society 14th International Congress (Munich, Germany), titled “Correct the autoimmune memory by Stem Cell Educator therapy in Caucasian type 1 diabetic subjects: phase I/II clinical trial”.

March 5, 2015, Dr.Yong Zhao was invited and gave a lecture at The XIII Congress of the Catalan Association of Diabetes (Barcelona, Spain).